Share Price | AEON Biopharma, Inc. Stock Analysis & Recommendation

Q: How big is AEON Biopharma, Inc.?

Market Cap: As of Jun 18, AEON Biopharma, Inc. has a market capitalization of 8.65 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, AEON Biopharma, Inc. reported net sales of 0.00 million and a net profit of 169.12 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -28.57 million and total assets of 3.14 million.

Q: What does AEON Biopharma, Inc. do?

Overview: AEON Biopharma, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Net Profit: 9 Million (Quarterly Results - Mar 2025) Market Cap: USD 8.65 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.27 Return on Equity: 855.59% Price to Book: -0.76Contact Details: Registrar Address: Not available.

Q: Is AEON Biopharma, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for AEON Biopharma, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness and a bearish KST on the monthly timeframe. While the weekly MACD and OBV show mild bullishness, the overall trend is influenced by the monthly Bollinger Bands and Dow Theory, both indicating mild bearishness. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -98.05% versus the benchmark's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

17.82 k

Shareholding (Sep 2025)

FII

0.49%

Held by 14 FIIs

DII

98.27%

Held by 1 DIIs

Promoter

0.00%

How big is AEON Biopharma, Inc.?

22-Jun-2025

As of Jun 18, AEON Biopharma, Inc. has a market capitalization of 8.65 million, categorizing it as a Micro Cap company, with reported net sales of 0.00 million and a net profit of 169.12 million over the latest four quarters. The company has shareholder's funds of -28.57 million and total assets of 3.14 million as of Dec 24.

View full answer

What does AEON Biopharma, Inc. do?

22-Jun-2025

AEON Biopharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting a net profit of $9 million for Q1 2025 and a market cap of $8.65 million. It has a negative P/E ratio, no dividend yield, and a high return on equity of 855.59%.

View full answer

Is AEON Biopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, AEON Biopharma, Inc. is in a mildly bearish trend, influenced by daily moving averages and a bearish KST, despite some mild bullish signals from the weekly MACD and OBV, with a year-to-date return of -98.05% compared to the S&P 500's 12.22%.

View full answer

Compare AEON Biopharma, Inc. with Similar Stocks

Enanta Pharmaceuticals, Inc.Lifecore Biomedical, Inc.Assertio Holdings, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 16 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.57

Return on Equity

467.23%

Price to Book

-0.83

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

19.57%

6 Months

-97.52%

1 Year

-98.98%

2 Years

-99.85%

3 Years

-99.84%

4 Years

-99.84%

5 Years

0.0%

AEON Biopharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-301.05%

EBIT to Interest (avg)

-16.04

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.27

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

16.96%

ROCE (avg)

ROE (avg)

0.01%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.82

EV to EBIT

-0.58

EV to EBITDA

-0.58

EV to Capital Employed

-1.50

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (1.24%)

Foreign Institutions

Held by 14 Foreign Institutions (0.49%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 27.42% vs -127.43% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.50",
          "val2": "-4.00",
          "chgp": "12.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.10",
          "val2": "-2.20",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.50",
          "val2": "-6.20",
          "chgp": "27.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 110.92% vs -631.18% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.70",
          "val2": "-52.70",
          "chgp": "47.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "69.70",
          "val2": "-332.40",
          "chgp": "120.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "42.00",
          "val2": "-384.60",
          "chgp": "110.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.50

-4.00

12.50%

Interest

0.00

Exceptional Items

-1.10

-2.20

50.00%

Consolidate Net Profit

-4.50

-6.20

27.42%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 27.42% vs -127.43% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-27.70

-52.70

47.44%

Interest

0.00

Exceptional Items

69.70

-332.40

120.97%

Consolidate Net Profit

42.00

-384.60

110.92%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 110.92% vs -631.18% in Dec 2023

All Annual Results

Company CV

About AEON Biopharma, Inc.

AEON Biopharma, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

AEON Biopharma, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is AEON Biopharma, Inc.?

Watch in Real-Time

What does AEON Biopharma, Inc. do?

Is AEON Biopharma, Inc. technically bullish or bearish?

Compare AEON Biopharma, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About AEON Biopharma, Inc.

Company Coordinates